Project Grant HT94252410538
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award of $718,858 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award, which runs from February 2025 to February 2028, aims to transform healthcare for military service members and the broader public through innovative and...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This federal Project Grant award, valued at $1,600,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports a 3-year research project titled "Potentiating Long-Lived Antitumor Effector CD8+ T Cells for TNBC Therapy" conducted by Northwestern University's Sponsored Research Division. The project aims to investigate innovative approaches to enhance the anti-tumor efficacy of CD8+ T cells for the...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
This federal Project Grant award, valued at $505,071.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by the University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The project will run from February 15, 2025 to February 14, 2028, focusing on advanced cancer research and exploring...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
The University of Texas Southwestern Medical Center received a three-year Project Grant award of $736,435 from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research to identify therapeutic vulnerabilities in estrogen receptor-positive and RB1-deficient breast cancers through February 2025. The Military Medical Research and Development program supports innovative biomedical research with the goals of...